§ FAQ
Twelve questions readers most often arrive with.
Direct, cited answers on prescription status, the historical regulatory record, mechanism, pharmacokinetics, the adult and pediatric trial data, and the contemporary compounding pathway.
Can sermorelin be prescribed?
Yes, in the regulatory sense that a state-licensed prescriber can write a prescription for a 503A patient-specific compounded preparation of sermorelin acetate, and a state-licensed compounding pharmacy can dispense it. There is no FDA-approved finished sermorelin product currently marketed in the United States; the original NDA 020443 branded formulation was discontinued in 2008 [3]. The active pharmaceutical ingredient remains legally compoundable under section 503A because it is a component of a previously-approved drug product, a pathway the FDA's January 7, 2025 final interim guidance explicitly preserved [13]. Practical access therefore runs through state-licensed pharmacies rather than through retail prescription channels.
Is sermorelin available by prescription?
It is available by prescription only through compounding pharmacies. The historical branded product (NDA 020443) is not commercially marketed. State-licensed pharmacies operating under section 503A dispense patient-specific compounded sermorelin against a valid prescription, and FDA-registered outsourcing facilities operating under section 503B prepare it for office-use distribution to prescribers under cGMP-like conditions [13]. The site you are reading is editorial and does not dispense, ship, or facilitate access to sermorelin or any compounded preparation.
What is the rx status of sermorelin?
Prescription-only, compounded. The active ingredient sits on a distinct regulatory pathway from non-approved research peptides: because sermorelin acetate was the active ingredient in a previously FDA-approved finished product, it qualifies as a component-of-previously-approved-drug under section 503A, and the FDA's 2025 final interim guidance reaffirmed that this pathway remains available to 503A and 503B facilities [13]. The FDA's 2013 Federal Register determination on the original product withdrawal explicitly recorded that the discontinuation was for commercial reasons rather than for safety or efficacy concerns [3].
What was the historical branded product and why was it discontinued?
The historical branded sermorelin acetate injection (NDA 020443) was approved on September 26, 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure, in 0.5 mg and 1.0 mg base/vial presentations for therapeutic use and a 0.05 mg base/ampoule presentation for diagnostic use [3]. The original manufacturer voluntarily discontinued the product in 2008, and the FDA formally withdrew the approval on June 18, 2009. The FDA's 2013 Federal Register determination on the withdrawal documented that it was a commercial decision and was not for reasons of safety or effectiveness [3]. Inferior height-velocity response relative to recombinant somatropin in head-to-head pediatric comparisons was the substantive contributor to the commercial decision.
Is sermorelin still on the FDA 503A bulks list?
Sermorelin was placed in interim Category 1 of the FDA 503A bulks-list nomination process prior to the January 7, 2025 final interim guidance. That guidance ended the forward-looking Category 1/2/3 nomination system for newly nominated bulk drug substances. The distinct regulatory pathway for sermorelin as a component of a previously-approved drug (the historical NDA 020443) remains available, and 503A and 503B facilities continue to compound sermorelin acetate under it [13]. A separate 2024 FDA action removing certain peptide bulks from Category 2 and scheduling Pharmacy Compounding Advisory Committee review reaffirmed sermorelin's distinct pathway as a previously-approved active, differentiating it from non-approved research peptides recently moved off Category 2.
What does the research say about sermorelin in adults?
The adult investigational record is smaller than the pediatric pivotal record but consistent in direction. The Khorram trial published in the Journal of Clinical Endocrinology & Metabolism in 1997 reported that nightly 10 mcg/kg subcutaneous administration over 16 weeks in 19 adults aged 55 to 71 raised nocturnal GH and IGF-1, with a mean 1.26 kg gain in lean body mass in men and improvements in insulin sensitivity [6]. The Vitiello NIH-funded six-month program at 14 mcg/kg nightly (approximately 1 mg) reported doubled 24-hour GH secretion, an approximately 40 percent rise in IGF-1, a roughly 5 percent reduction in body fat, and 5-to-7 percent improvements in cognitive processing speed [8]. The class-validating Baker trial of the structurally related stabilized analog tesamorelin reported significant executive-function improvement, a 117 percent rise in IGF-1 within the physiologic range, and a 7.4 percent reduction in body fat over 20 weeks at 1 mg subcutaneous daily in 152 older adults including 66 with mild cognitive impairment [7].
What is the half-life of sermorelin?
Approximately 11 to 12 minutes in plasma, after both intravenous and subcutaneous administration, in a 12-subject normal-volunteer pharmacokinetic study [5]. Mean clearance is 2.4 to 2.8 L/min; subcutaneous absolute bioavailability is approximately 6 percent; peak plasma concentration occurs at 5 to 20 minutes after subcutaneous dosing. Less than 5 percent of the dose remains circulating at 60 minutes. The biological signal — the induced GH pulse and the downstream hepatic IGF-1 response — persists hours to days after the parent peptide has cleared, which is why the once-nightly schedule has been the operational standard in essentially every adult study despite the brief plasma half-life.
How does sermorelin differ from recombinant growth hormone?
Sermorelin acts upstream at the pituitary, asking the somatotrophs to release their own stored GH; recombinant human GH (somatropin) bypasses the pituitary and presents an exogenous GH exposure profile directly. The pulsatility of the resulting GH signal is the structural difference: sermorelin produces a physiologic GH pulse, because somatostatin negative feedback remains intact and constrains the response. Recombinant GH does not preserve that pulsatility. Walker's 2006 review summarized the consequences — preservation of the somatotrophic axis rather than its bypass, reduced risk of supraphysiologic IGF-1, and minimized tachyphylaxis with GHRH-class stimulation relative to direct GH replacement [9]. The pediatric height-velocity response in head-to-head trials nonetheless modestly favored once-daily somatropin, which was a substantive contributor to the 2008 commercial withdrawal of the branded sermorelin product [1].
What is sermorelin's mechanism of action?
Sermorelin is a GHRH receptor agonist. It binds GHRHR on anterior pituitary somatotrophs, activating Gs-coupled cAMP/PKA signaling and a parallel MAPK arm that together drive GH gene transcription and the release of stored GH from secretory granules [12]. The released GH circulates briefly and induces hepatic IGF-1 production, which mediates most of the anabolic and metabolic downstream effects. Because the upstream stimulus is GHRHR rather than the GH receptor itself, somatostatin negative feedback is preserved and the resulting GH profile is pulsatile. GHRH-class peptides also have direct, GH-independent actions: activation of sleep-regulatory preoptic-hypothalamus neurons augmenting NREM sleep duration and slow-wave EEG power [12], and preclinical cardioprotective effects in rodent ischemia-reperfusion and pressure-overload models [11].
What are the documented side effects?
The reported adverse-event profile from pediatric pivotal trials and adult investigational studies has been mild and predominantly local: transient facial flushing, injection-site reactions (pain, erythema, swelling) in approximately one in six patients, and occasional headache. Serious adverse events were rare, and no clinically significant changes in routine laboratory values were reported [14]. Documented contraindications include active malignancy, pregnancy, untreated severe hypothyroidism, and hypersensitivity to sermorelin or any vial component. Long-term safety data in healthy adults remain limited relative to the pediatric record, because the adult investigational studies were of weeks-to-months duration rather than multi-year.
How is sermorelin handled and stored?
Sermorelin is supplied as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water for injection — sterile water containing 0.9 percent benzyl alcohol as a preservative — before administration [17]. The diluent is introduced down the side of the vial wall and the vial is gently swirled rather than shaken; the peptide chain is denatured by vigorous agitation. The reconstituted solution is stored at 2 to 8 degrees Celsius, protected from light and from elevated temperature, with a labeled beyond-use date consistent with USP <797> peptide compounding guidance. The lyophilized vial itself is shelf-stable when refrigerated until reconstitution.
Is sermorelin prohibited in sport?
Yes. The World Anti-Doping Agency prohibits GHRH and its analogs — including sermorelin — under Code section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) for in- and out-of-competition athletes. Sport-tested athletes should consult their governing body and the current WADA Prohibited List directly, since classifications and analytical methods evolve year to year.